A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure
Broadly neutralizing antibodies (bnAbs) to HIV delineate vaccine targets and are
prophylactic and therapeutic agents. Some of the most potent bnAbs target a quaternary …
prophylactic and therapeutic agents. Some of the most potent bnAbs target a quaternary …
Immune responses to retroviruses
A Saez-Cirion, N Manel - Annual review of immunology, 2018 - annualreviews.org
Retroviruses are genome invaders that have shared a long history of coevolution with
vertebrates and their immune system. Found endogenously in genomes as traces of past …
vertebrates and their immune system. Found endogenously in genomes as traces of past …
Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine
design and are potential therapeutic agents. We identified SF12 and related bNAbs with up …
design and are potential therapeutic agents. We identified SF12 and related bNAbs with up …
Rapid and focused maturation of a VRC01-class HIV broadly neutralizing antibody lineage involves both binding and accommodation of the N276-glycan
Summary The VH1-2 restricted VRC01-class of antibodies targeting the HIV envelope CD4
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of …
Chronic viral infection promotes efficient germinal center B cell responses
B Fallet, Y Hao, M Florova, K Cornille, AV de Los Aires… - Cell reports, 2020 - cell.com
Persistent viral infections subvert key elements of adaptive immunity. To compare germinal
center (GC) B cell responses in chronic and acute lymphocytic choriomeningitis virus …
center (GC) B cell responses in chronic and acute lymphocytic choriomeningitis virus …
Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity
AS Thomas, Y Moreau, W Jiang, JE Isaac, A Ewing… - Cell Reports …, 2021 - cell.com
In humans, pre-existing anti-HIV-1 neutralizing antibodies (nAbs) have not been associated
with decreased HIV-1 acquisition. Here, we evaluate antibody-dependent cellular …
with decreased HIV-1 acquisition. Here, we evaluate antibody-dependent cellular …
HIV/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived virus-like particles or …
The nonreplicating attenuated poxvirus vector NYVAC expressing clade C (CN54) HIV-1
Env (gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in …
Env (gp120) and Gag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in …
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
A small fraction of HIV-1-infected humans develop broadly neutralizing antibodies (bNAbs)
against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus …
against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus …
Maedi-visna virus as a model for HIV
V Andrésdóttir - 2018 - opinvisindi.is
Maedi-visna virus (MVV) is a lentivirus of sheep causing inflammation in many organs,
primarily the lungs and CNS. HIV and SIV also belong to the lentivirus genus of retroviruses …
primarily the lungs and CNS. HIV and SIV also belong to the lentivirus genus of retroviruses …
Limited evidence for a relationship between HIV-1 glycan shield features in early infection and the development of neutralization breadth
Identifying whether viral features present in acute HIV-1 infection predetermine the
development of neutralization breadth is critical to vaccine design. Incorporating such …
development of neutralization breadth is critical to vaccine design. Incorporating such …